Latest filing published 29 Aug 2025 for iTeos Therapeutics, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Michel Detheux is a declared insider of iTeos Therapeutics, Inc. (chief executive), with filings sourced from SEC (Form 4). The record holds 20 filings, for trades running from 14 June 2021 to 29 August 2025.
Every open-market trade on record is a sale: 11 sales worth €2.3M. The rest of the record consists of 3 share grants and 5 option exercises.
On 29 August 2025 came the latest disclosure, a transaction in iTeos Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
20 of 20 declarations